The USPTO has issued a patent (US12583933B2) to BIOTHEUS INC. for an anti-CD73 antibody or antigen-binding fragment thereof, along with related nucleic acid molecules, immunoconjugates, bispecific molecules, and pharmaceutical compositions. The patent also covers the use of these agents in enhancing immune response and treating tumors. This grant signifies a new intellectual property right for the assignee concerning novel therapeutic agents in the field of immunology and disease therapy.

This patent grant does not impose new compliance obligations on regulated entities. However, it establishes exclusive rights for BIOTHEUS INC. regarding the patented technology. Companies operating in the pharmaceutical and biotechnology sectors, particularly those involved in cancer immunotherapy or developing treatments targeting CD73, should be aware of this patent to avoid potential infringement and to inform their own research and development strategies.